Verastem, Inc. (2VSA.F)
EUR 4.28
(-35.15%)
EUR 4.28
(-35.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -72.93 Million USD | -18.77% |
| 2021 | -61.4 Million USD | -24.41% |
| 2020 | -49.36 Million USD | 62.7% |
| 2019 | -132.34 Million USD | -39.63% |
| 2018 | -94.78 Million USD | -39.79% |
| 2017 | -67.8 Million USD | -83.24% |
| 2016 | -37 Million USD | 36.42% |
| 2015 | -58.19 Million USD | -8.57% |
| 2014 | -53.6 Million USD | -29.48% |
| 2013 | -41.4 Million USD | -28.46% |
| 2012 | -32.23 Million USD | -135.29% |
| 2011 | -13.69 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -18.27 Million USD | 34.86% |
| 2024 Q1 | -28.05 Million USD | 9.89% |
| 2023 Q3 | -21.3 Million USD | -5.01% |
| 2023 Q2 | -20.29 Million USD | -4.9% |
| 2023 Q1 | -19.34 Million USD | -14.83% |
| 2023 Q4 | -31.13 Million USD | -46.13% |
| 2022 Q1 | -16.98 Million USD | -2.84% |
| 2022 Q4 | -16.84 Million USD | 4.87% |
| 2022 Q3 | -17.7 Million USD | 17.26% |
| 2022 Q2 | -21.4 Million USD | -26.04% |
| 2022 FY | -72.93 Million USD | -18.77% |
| 2021 FY | -61.4 Million USD | -24.41% |
| 2021 Q2 | -15.94 Million USD | -13.01% |
| 2021 Q3 | -14.84 Million USD | 6.89% |
| 2021 Q4 | -16.51 Million USD | -11.22% |
| 2021 Q1 | -14.1 Million USD | 15.79% |
| 2020 Q3 | 15.01 Million USD | 170.62% |
| 2020 Q4 | -16.75 Million USD | -211.57% |
| 2020 Q2 | -21.26 Million USD | 19.33% |
| 2020 Q1 | -26.35 Million USD | 20.82% |
| 2020 FY | -49.36 Million USD | 62.7% |
| 2019 Q1 | -34.67 Million USD | -1.2% |
| 2019 Q2 | -38.27 Million USD | -10.4% |
| 2019 Q3 | -26.1 Million USD | 31.81% |
| 2019 FY | -132.34 Million USD | -39.63% |
| 2019 Q4 | -33.29 Million USD | -27.54% |
| 2018 FY | -94.78 Million USD | -39.79% |
| 2018 Q4 | -34.25 Million USD | -58.83% |
| 2018 Q2 | -18.19 Million USD | 12.36% |
| 2018 Q3 | -21.56 Million USD | -18.55% |
| 2018 Q1 | -20.76 Million USD | -15.01% |
| 2017 Q4 | -18.05 Million USD | 21.98% |
| 2017 FY | -67.8 Million USD | -83.24% |
| 2017 Q3 | -23.13 Million USD | -71.81% |
| 2017 Q2 | -13.46 Million USD | -2.43% |
| 2017 Q1 | -13.14 Million USD | -11.42% |
| 2016 Q4 | -11.8 Million USD | -46.42% |
| 2016 Q3 | -8.05 Million USD | 7.46% |
| 2016 Q1 | -8.43 Million USD | 29.49% |
| 2016 Q2 | -8.7 Million USD | -3.26% |
| 2016 FY | -37 Million USD | 36.42% |
| 2015 Q3 | -15.53 Million USD | -0.47% |
| 2015 Q4 | -11.96 Million USD | 23.0% |
| 2015 Q2 | -15.46 Million USD | -1.44% |
| 2015 Q1 | -15.24 Million USD | -8.89% |
| 2015 FY | -58.19 Million USD | -8.57% |
| 2014 Q3 | -13.38 Million USD | -2.3% |
| 2014 Q4 | -13.99 Million USD | -4.56% |
| 2014 Q1 | -13.13 Million USD | -15.28% |
| 2014 Q2 | -13.08 Million USD | 0.36% |
| 2014 FY | -53.6 Million USD | -29.48% |
| 2013 Q2 | -10.28 Million USD | -13.25% |
| 2013 Q1 | -9.08 Million USD | -13.85% |
| 2013 FY | -41.4 Million USD | -28.46% |
| 2013 Q4 | -11.39 Million USD | -7.04% |
| 2013 Q3 | -10.64 Million USD | -3.5% |
| 2012 Q1 | -6.92 Million USD | -15.08% |
| 2012 Q2 | -6.89 Million USD | 0.46% |
| 2012 Q3 | -10.43 Million USD | -51.25% |
| 2012 FY | -32.23 Million USD | -135.29% |
| 2012 Q4 | -7.97 Million USD | 23.53% |
| 2011 Q4 | -6.02 Million USD | -48.75% |
| 2011 Q3 | -4.04 Million USD | -62.86% |
| 2011 FY | -13.69 Million USD | 0.0% |
| 2011 Q2 | -2.48 Million USD | -116.84% |
| 2011 Q1 | -1.14 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 110.564% |
| CureVac N.V. | -274.2 Million EUR | 73.401% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 150.827% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 150.827% |
| BRAIN Biotech AG | -6.71 Million EUR | -986.18% |
| Formycon AG | -369 Thousand EUR | -19666.125% |
| Heidelberg Pharma AG | -21.2 Million EUR | -243.884% |
| Medigene AG | -16.14 Million EUR | -351.65% |